Pure Global

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris - Trial NCT06063473

Access comprehensive clinical trial information for NCT06063473 through Pure Global AI's free database. This Phase 1 trial is sponsored by Taro Pharmaceuticals USA and is currently Completed. The study focuses on Acne Vulgaris. Target enrollment is 762 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06063473
Phase 1
Completed
drug
Trial Details
ClinicalTrials.gov • NCT06063473
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris
A Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-group Study, Comparing Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A, Inc.) and to AKLIEF® Cream (Trifarotene 0.005%,Galderma) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris

Study Focus

Acne Vulgaris

Trifarotene Cream 0.005%

Interventional

drug

Sponsor & Location

Taro Pharmaceuticals USA

Hawthorne, United States of America

Timeline & Enrollment

Phase 1

Feb 22, 2023

Jul 13, 2023

762 participants

Primary Outcome

Demonstration in Therapeutic Equivalence & Safety of the Investigational Product

Summary

To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro
 Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris

ICD-10 Classifications

Acne vulgaris
Acne
Acne, unspecified
Acné excoriée
Other acne

Data Source

ClinicalTrials.gov

NCT06063473

Non-Device Trial